SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference being held November 9-11, 2026 in Boston, MA.
Guggenheim Securities 3rd Annual Healthcare Innovation Conference
Format: Fireside Chat and 1x1 Meetings
Date: November 9, 2026
Time: 9:00 – 9:25 a.m. ET
If you are interested in meeting with Adagene management during the conference, please reach out to your Guggenheim representative.
A webcast of the fireside chat will be accessible in the Investors section of the Company’s website at https://www.adagene.com for at least 30 days following the conference.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, muzastotug (ADG126), is a masked anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 on regulatory T cells (Tregs) in the tumor microenvironment. Muzastotug is currently being evaluated in Phase 1b/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy, particularly in microsatellite stable (MSS) metastatic colorectal cancer (CRC). The FDA has granted Fast Track designation to muzastotug in combination with pembrolizumab for adult patients with MSS metastatic CRC without current or active liver metastases. Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc-empowered antibodies, antibody-drug conjugates, and bispecific and multispecific T-cell engagers.
